A decade of fragment-based drug design: Strategic advances and lessons learned

Nature Reviews Drug Discovery

Volumn 6, Issue 3, 2007, Pages 211-219

  Hajduk, Philip J ^a   Greer, Jonathan ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3ALPHA HYDROXYSTEROID DEHYDROGENASE INHIBITOR; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ABT 518; AT 13387; AT 7519; AT 9283; AT 9311; AURORA KINASE INHIBITOR; CASPASE 3 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; ENZYME INHIBITOR; ERYTHROID KINASE INHIBITOR; FK 506 BINDING PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; LIPID BINDING PROTEIN INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; METHIONYL AMINOPEPTIDASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PHOSPHODIESTERASE INHIBITOR; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; SNS 314; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; STROMELYSIN; SURVIVIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; CLINICAL TRIAL; COMBINATORIAL CHEMISTRY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DRUG TARGETING; GENE SEQUENCE; HIGH THROUGHPUT SCREENING; HUMAN; INVESTMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; TECHNOLOGY; X RAY CRYSTALLOGRAPHY;

DECISION MAKING, ORGANIZATIONAL; DRUG DESIGN; DRUG INDUSTRY; LIGANDS; MOLECULAR STRUCTURE; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 33847381100     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2220     Document Type: Review

References (78)

1. Butcher, E. C. Can cell systems biology rescue drug discovery? Nature Rev. Drug Discov. 4, 461-467 (2005).
2. van der Greef, J. & McBurney, R. N. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nature Rev. Drug Discov. 4, 961-967 (2005).
3. Hardy, L. W. & Peet, N. P. The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets. Drug Discov. Today 9, 117-126 (2004).
4. Betz, U. A., Farquhar, R. & Ziegelbauer, K. Genomics: Success or failure to deliver drug targets? Curr. Opin. Chem. Biol. 9, 387-391 (2005).
5. Zambrowicz, B. P. & Sands, A. T. Knockouts model the 100 best-selling drugs - will they model the next s100? Nature Rev. Drug Discov. 2, 38-51 (2003).
6. Macarron, R. Critical review of the role of HTS in drug discovery. Drug Discov. Today 11, 277-279 (2006).
7. Silverman, L., Campbell, R. & Broach, J. R. New assay technologies for high-throughput screening. Curr. Op. Chem. Biol. 2, 397-403 (1998).
8. Oprea, T. I. & Matter, H. Integrating virtual screening in lead discovery. Curr. Opin. Chem. Biol. 8, 349-358 (2004).
9. Shoichet, B. K. Virtual screening of chemical libraries. Nature 432, 862-865 (2004).
10. Scapin, G. Structural biology and drug discovery. Curr. Pharm. Des. 12, 2087-2097 (2006).
11. Brown, D. & Superti-Furga, G. Rediscovering the sweet spot in drug discovery. Drug Discov. Today 8, 1067-1077 (2003).
12. Bohm, H. J. Site-directed structure generation by fragment-joining. Persp. Drug. Disc. Design 3, 21-33 (1995).
13. Miranker, A. & Karplus, M. Functionality maps of binding sites: A multiple copy simultaneous search method. Proteins 11, 29-34 (1991).
14. Hajduk, P. J., Meadows, R. P. & Fesik, S. W. NMR-based screening in drug discovery. Q. Rev. Biophys. 32, 211-240 (1999).
15. Shuker, S. B., Hajduk, P. J., Meadows, R. P. & Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274, 1531-1534 (1996).
16. Hajduk, P. J. et al. Discovery of potent nonpeptide inhibitors of stromelysin using SAR by NMR. J. Am. Chem. Soc. 119, 5818-5827 (1997).
17. Beckett, R. P., Davidson, A. H., Drummond, A. H., Huxley, P. & Whittaker, M. Recent advances in matrix metalloproteinase inhibitor research. Drug. Disc. Today 1, 16-26 (1996).
18. Wada, C. K. et al. Phenoxyphenyl sulfone N-formylhydroxylamines (Retorhydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors. J. Med. Chem. 45, 219-232 (2002).
19. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
20. Kirkin, V., Joos, S. & Zornig, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 1644, 229-249 (2004).
21. Petros, A. M. et al. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J. Med. Chem. 49, 656-663 (2006).
22. Lepre, C. A., Moore, J. M. & Peng, J. W. Theory and applications of NMR-based screening in pharmaceutical research. Chem. Rev. 104, 3641-3676 (2004).
23. Meyer, B. & Peters, T. NMR spectroscopy techniques for screening and identifying ligand binding to protein receptors. Angew. Chem. Int. Ed. Engl. 42, 864-890 (2003).
24. Dalvit, C. et al. A general NMR method for rapid, efficient, and reliable biochemical screening. J. Am. Chem. Soc. 125, 14620-14625 (2003).
25. London, R. E. Theoretical analysis of the inter-ligand overhauser effect: A new approach for mapping structural relationships of macromolecular ligands. J. Magn. Reson. 141, 301-311 (1999).
26. Becattini, B. et al. Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid. Proc. Natl Acad. Sci. USA 103, 12602-12606 (2006).
27. Lin, M., Shapiro, M. J. & Wareing, J. R. Diffusion-edited NMR-affinity NMR for direct observation of molecular interactions. J. Am. Chem. Soc. 119, 5249-5250 (1997).
28. Fejzo, J. et al. The SHAPES strategy: An NMR-based approach for lead generation in drug discovery. Chem. Biol. 6, 755-769 (1999).
29. Stockman, B. J. NMR spectroscopy as a tool for structure-based drug design. Prog. Nucl. Magn. Reson. Spectrosc. 33, 109-151 (1998).
30. Dalvit, C. et al. NMR-based screening with competition water-ligand observed via gradient spectroscopy experiments: Detection of high-affinity ligands. J. Med. Chem. 45, 2610-2614 (2002).
31. Nienaber, V. L. et al. Discovering novel ligands for macromolecules using X-ray crystallographic screening. Nature Biotechnol. 18, 1105-1108 (2000).
32. Carr, R. A., Congreve, M., Murray, C. W. & Rees, D. C. Fragment-based lead discovery: Leads by design. Drug Discov. Today 10, 987-992 (2005).
33. Erlanson, D. A., Wells, J. A. & Braisted, A. C. Tethering: fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 33, 199-223 (2004).
34. Martin, Y. C. Challenges and prospects for computational aids to molecular diversity. Perspect. Drug Discov. Des. 7-8, 159-172 (1997).
35. Jacoby, E. et al. Key aspects of the Novartis compound collection enhancement project for the compilation of a comprehensive chemogenomics drug discovery screening collection. Curr. Top. Med. Chem. 5, 397-411 (2005).
36. Davis, A. M., Keeling, D. J., Steele, J., Tomkinson, N. P. & Tinker, A. C. Components of successful lead generation. Curr. Top. Med. Chem. 5, 421-439 (2005).
37. Fink, T., Bruggesser, H. & Reymond, J. L. Virtual exploration of the small-molecule chemical universe below 160 Daltons. Angew. Chem. Int. Ed. Engl. 44, 1504-1508 (2005).
38. Hann, M. M., Leach, A. R. & Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery. J. Chem. Inf. Comput. Sci. 41, 856-864 (2001).
39. Schuffenhauer, A. et al. Library design for fragment based screening. Curr. Top. Med. Chem. 5, 751-762 (2005).
40. Hajduk, P. J., Huth, J. R. & Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data. J. Med. Chem. 48, 2518-2525 (2005).
41. McGovern, S. L., Caselli, E., Grigorieff, N. & Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 45, 1712-1722 (2002).
42. Huth, J. R. et al. ALARM NMR: A rapid and robust experimental method to detect reactive false positives in biochemical screens. J. Am. Chem. Soc. 127, 217-224 (2005).
43. Hajduk, P. J. & Burns, D. J. Integration of NMR and high-throughput screening. Comb. Chem. High Throughput Screen. 5, 613-621 (2002).
44. Qian, J. et al. Discovery of novel inhibitors of Bcl-xL using multiple high-throughput screening platforms. Anal. Biochem. 328, 131-138 (2004).
45. Abad-Zapatero, C. & Metz, J. T. Ligand efficiency indices as guideposts for drug discovery. Drug Discov. Today 10, 464-469 (2005).
46. Hopkins, A. L., Groom, C. R. & Alex, A. Ligand efficiency: A useful metric for lead selection. Drug Discov. Today 9, 430-431 (2004).
47. Oprea, T. I., Davis, A. M., Teague, S. J. & Leeson, P. D. Is there a difference between leads and drugs? A historical perspective. J. Chem. Inf. Comput. Sci. 41, 1308-1315 (2001).
48. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249 (2000).
49. Hajduk, P. J. Fragment-based drug design: How big is too big? J. Med. Chem. 49, 6972-6976 (2006).
50. Lipinski, C., Lombardo, F., Dominy, B. & Feeney, P. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 23, 3-25 (1997).
51. Wunberg, T. et al. Improving the hit-to-lead process: Data-driven assessment of drug-like and lead-like screening hits. Drug Discov. Today 11, 175-180 (2006).
52. Wolfson, W. Fragmentary solutions Astex Therapeutics puts the pieces together. Chem. Biol. 13, 799-801 (2006).
53. Barker, J., Courtney, S., Hesterkamp, T., Ullmann, D. & Whittaker, M. Fragment screening by biochemical assay. Expert Opin. Drug Discov. 1, 225-236 (2006).
54. Vanwetswinkel, S. et al. TINS, target immobilized NMR screening: An efficient and sensitive method for ligand discovery. Chem. Biol. 12, 207-216 (2005).
55. Lehn, J. M. & Eliseev, A. V. Dynamic combinatorial chemistry. Science 291, 2331-2332 (2001).
56. Otto, S., Furlan, R. L. & Sanders, J. K. Recent developments in dynamic combinatorial chemistry. Curr. Opin. Chem. Biol. 6, 321-327 (2002).
57. Vajda, S. & Guarnieri, F. Characterization of protein-ligand interaction sites using experimental and computational methods. Curr. Opin. Drug Discov. Devel. 9, 354-362 (2006).
58. Hajduk, P. J. et al. Design of adenosine kinase inhibitors from the NMR-based screening of fragments. J. Med. Chem. 43, 4781-4786 (2000).
59. Liu, G. et al. Novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/ intracellular adhesion molecule-1 interaction. 2. Mechanism of inhibition and structure-based improvement of pharmaceutical properties. J. Med. Chem. 44, 1202-1210 (2001).
60. Szczepankiewicz, B. G. et al. Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J. Am. Chem. Soc. 125, 4087-4096 (2003).
61. Sanders, W. J. et al. Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization. J. Med. Chem. 47, 1709-1718 (2004).
62. Astex Therapeutics. Clincal candidates: AT13387. Astex Therapeutics web site [online], .
63. Gill, A. L. et al. Identification of novel p38α MAP kinase inhibitors using fragment-based lead generation. J. Med. Chem. 48, 414-426 (2005).
64. Lange, G. et al. Requirements for specific binding of low affinity inhibitor fragments to the SH2 domain of (pp60)Src are identical to those for high affinity binding of full length inhibitors. J. Med. Chem. 46, 5184-5195 (2003).
65. Lesuisse, D. et al. SAR and X-ray. A new approach combining fragment-based screening and rational drug design: Application to the discovery of nanomolar inhibitors of Src SH2. J. Med. Chem. 45, 2379-2387 (2002).
66. Forino, M. et al. Efficient synthetic inhibitors of anthrax lethal factor. Proc. Natl Acad. Sci. USA 102, 9499-9504 (2005).
67. Card, G. L. et al. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nature Biotech. 23, 201-207 (2005).
68. Oblak, M. et al. In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. Bioorg. Med. Chem. Lett. 15, 5207-5210 (2005).
69. Blaney, J., Nienaber, V. L. & Burley, S. in Fragment-Based Approaches in Drug Discovery (eds Jahnke, W. & Erlanson, D. A.) 215-248 (Wiley-VCH, Weinheim, Germany, 2006).
70. Warner, S. L. et al. Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol. Cancer Ther. 5, 1764-1773 (2006).
71. Zhu, Z. et al. Heterocyclic aspartyl protease inhibitors. US Patent 20060111370 (2006).
72. Chan, T-Y. et al. Kinase inhibitors. European Patent WO2006081230 (2006).
73. Sunesis. Pipeline programs: SNS-314. Sunesis web site [online], .
74. Braisted, A. C. et al. Discovery of a potent small molecule IL-2 inhibitor through fragment assembly. J. Am. Chem. Soc. 125, 3714-3715 (2003).
75. Choong, I. C. et al. Identification of potent and selective small-molecule inhibitors of caspase-3 through the use of extended tethering and structure-based drug design. J. Med. Chem. 45, 5005-5022 (2002).
76. O'Brien, T. et al. Structural analysis of caspase-1 inhibitors derived from Tethering. Acta Crystallograph. Sect. F Struct. Biol. Cryst. Commun. 61, 451-458 (2005).
77. Sem, D. in Fragment-Based Approaches in Drug Discovery (eds Jahnke, W. & Erlanson, D. A.) 149-177 (Wiley-VCH, Weinheim, Germany, 2006).
78. Moore, J. et al. Leveraging structural approaches: Applications of NMR-based screening and X-ray crystallography for inhibitor design. J. Synchrotron Radiat. 11, 97-100 (2004).